Global launch status of Eltrombopag/Eltrombopag

Eltrombopag/The launch of Eltrombopag brings a new treatment option to adult patients with chronic immune (idiopathic) thrombocytopenia (ITP). It becomes an important hope for patients when traditional medications or splenectomy surgery fail to effectively relieve symptoms. ITP is a troublesome condition that causes abnormal bruising or bleeding due to an abnormally low number of platelets in the blood. In addition, eltrombopag is used to treat thrombocytopenia in patients with chronic hepatitis C, helping them initiate and continue interferon therapy.

Since November 2008Eltrombopag has been officially approved by the U.S. Food and Drug Administration (FDA) under its U.S. trade name Promacta and entered the U.S. market. Seven years later, in 2017, it was listed as a standard drug for the treatment of aplastic anemia in the United States, which shows its efficacy and influence. In 2010, after a rigorous evaluation, the European Medicines Agency (EMA) believed that the therapeutic benefits of eltrombopag are significant and the benefits far outweigh the potential risks, so it authorized its use within the EU. In Europe it is known under the trade name Revolade and is widely sold outside the United States.

Eltrombopag has also entered the Chinese market. In 2022, after strict approval by the State Food and Drug Administration, it was officially launched in China as Eltrombopag ethanolamine tablets (Revolade), and was included in the reimbursement scope of Class B medical insurance, bringing good news to more Chinese patients.

In summary, eltrombopag/Eltrombopag, as a highly effective and widely used drug, has been launched globally and has brought hope to many patients. At the same time, its diverse price options also make this treatment affordable for more patients.